Core Viewpoint - The announcement indicates that Tianen Pharmaceutical has received a production registration approval for Safinamide Mesylate Tablets from the National Medical Products Administration, which is a significant step for the company in expanding its product offerings in the Parkinson's disease treatment market [1]. Company Summary - Tianen Pharmaceutical's wholly-owned subsidiary, Anhui Tianen Pharmaceutical Co., Ltd., has received the acceptance notice for the drug registration application for Safinamide Mesylate Tablets [1]. - Safinamide Mesylate is a selective MAO-B inhibitor primarily used for treating adult patients with idiopathic Parkinson's disease, serving as an adjunct therapy to stable doses of L-dopa alone or in combination with other PD treatments for patients experiencing mid to late-stage fluctuations [1].
泰恩康：甲磺酸沙非胺片药品注册上市许可申请获受理